Professor Outterson teaches health care law at Boston University, where he co-directs the Health Law Program. He serves as the Executive Director and Principal Investigator for CARB-X, a $480M international public-private partnership to accelerate global antibacterial innovation. Key partners in CARB-X include the US Government (BARDA & NIAID), the Wellcome Trust, the UK Government (GAMRIF, DHSC), the German Federal Ministry of Education and Research, and the Bill & Melinda Gates Foundation. Professor Outterson's research work focuses on the law and economics of antimicrobial resistance (available at Google Scholar). He served as a senior author on many key research reports on antibiotic innovation, including Chatham House, ERG, DRIVE-AB, and the Lancet Commission. Professor Outterson was given the 2015 Leadership Award by the Alliance for the Prudent Use of Antibiotics for his research and advocacy work. He has testified before Congress, Parliamentary working groups, WHO, and several state legislatures. CARB-X was launched in 2016 and, under Prof Outterson's leadership, has become the world's largest and most innovative antibiotic accelerator.